Prot #ACE-LY-003: An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects with B-cell Non-Hodgkin Lymphoma

Project: Research project

Project Details

StatusActive
Effective start/end date8/21/19 → 12/31/23

Funding

  • Syneos Health, Inc. (Prot #ACE-LY-003)
  • Acerta Pharma, LLC (Prot #ACE-LY-003)